Appliation of compound mylabris capsules combined with concurrent chemoradiotherapy in cervical carcinoma

Abstract

Objective To observe the clinical efficacy and adverse reactions of compound mylabris capsules combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer. Methods From September 2013 to September 2014, we collected 80 patients with stage ⅡB-ⅣA cervical cancer who were admitted to Cancer Center of Affiliated People′s Hospital of Hubei University of Medicine. They were divided into the observation group (n=40) and control group (n=40) according to random number table. Patients of observation group were treated with compound mylabris capsules combined with chemo-radiotherapy, and patients of the control group were treated with the concurrent chemoradiotherapy alone. TP scheme of paclitaxel plus cisplatin was used in chemotherapy. Intensity-modulated radiation therapy (IMRT) and intracavitary brachytherapy was used in radiotherapy. The effective rates, Karnofsky Performance Status (KPS) scores, and recent adverse reactions in the two groups were compared. Results The short-time effective rates in the observation group and control group were 97.5% and 95.0% respectively, with no significant difference (χ2=0.346, P=0.556). The grade Ⅲ-Ⅳ adverse reactions in the observation group and control group included leucopenia (80.0% vs. 95.0%), lower hemoglobin (22.5% vs.45.0%), thrombocytopenia (60.0% vs. 82.5%), radioactive urocystitis (5.0% vs. 30.0%), radioactive proctitis (10.0% vs. 30.0%), with significant differences (χ2=4.114, P=0.043; χ2=4.528, P=0.033; χ2=4.943, P=0.026; χ2=8.658, P=0.003; χ2=5.000, P=0.025). The KPS score in the observation group was higher than that in the control group (90 vs. 70), with significant difference (Z=4.523, P=0.000). Conclusion The clinical efficacy of compound mylabris capsules combined with concurrent chemoradiotherapy and chemoradiotherapy alone for patients with locally advanced cervical cancer are similar. Compound mylabris capsules can reduce the rates of adverse reactions such as leucopenia, lower hemoglobin, thrombocytopenia, radioactive urocystitis and radioactive proctitis, and can improve KPS score, which plays a role of reliving toxicity. Key words: Uterine cervical neoplasms; Radiotherapy; Chemotherapy, adjuvant; Drug therapy